Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

  • STATUS
    Recruiting
  • End date
    Jan 28, 2024
  • participants needed
    102
  • sponsor
    Fudan University
Updated on 28 January 2021

Summary

The aim of the study is to determine if intervening with combined local therapy and chemotherapy prior to chemotherapy alone in patients with oligorecurrent and oligometastatic esophageal squamous cell carcinoma led to significant improvements in progression-free survival (PFS).

Details
Condition Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma
Treatment Chemotherapy, Radiation, Surgery or Radiofrequency ablation
Clinical Study IdentifierNCT03904927
SponsorFudan University
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma?
Do you have any of these conditions: Do you have Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma??
Do you have any of these conditions: Do you have Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma??
Patients with oligometastatic diseases and pathologically confirmed esophageal squamous cell carcinoma after initial radical treatment [i.e., completely resected surgery or radical (chemo)radiotherapy], the primary esophageal sites are controlled
Note
Definition of metastasis: patients with distant organ metastases or non-regional lymph node metastases; or patients with distant organs/non-regional lymph node metastases and regional lymph node metastases as defined in the eighth edition of the AJCC. Patients with only regional lymph node metastasis and/or anastomotic/esophageal recurrence are not eligible for enrollment
According to the classification of oligometastatic disease, oligometastasis including synchronous oligometastasis, metachronous oligometastasis, and repeat oligometastasis could be enrolled in this trial
In visceral metastases or non-regional lymph node metastases, at least one metastatic lesion obtains pathological confirmation
The total number of metastases is 4 or less and maximum 3 metastases in any single organ system (i.e. lung, liver). The maximum diameter for each lesion should be less than 5 cm
Each lesion was counted separately at the time of registration and contributed to the total number of metastases.If regional recurrences are existed, all positive regional lymph nodes are count together as one lesion. For non-regional lymph node metastases, adjacent metastatic lymph nodes can be treated as one lesion
Lesions that have subsided during previous treatment (i.e., were no longer visible on CT or had eliminated affinity on PET-CT) are not included in the total number. For patients with synchronous oligometastasis, the controlled primary tumor and regional lymph nodes on imaging are counted toward the total of 4
All metastases of current diagnosis did not receive local treatment such as radiotherapy, surgery, radiofrequency ablation before enrollment
Previous chemotherapy was allowed, but no anti-tumor medication was received within 3 months prior to the start of treatment
The measurable lesion was determined by the investigator based on the RECIST 1.1 assessment. A lesion located in a previous radiotherapy area can be considered a target lesion if it is confirmed to progress and is considered to be measurable according to RECIST 1.1
The patient is over 18 years old and has an ECOG score of 0-1
Estimated survival time >12 weeks
The function of vital organs meets the following requirements
Neutrophil absolute count (ANC) 1.5 10^9 / L
platelets 100 10^9 / L
Hemoglobin 9g / dL
serum albumin 2.8g / dL
Total bilirubin 1.5 ULN, ALT, AST and / or AKP 2.5 ULN; if there is liver metastasis, ALT and / or AST 5 ULN; if there is liver metastasis or bone metastasis AKP 5 ULN
serum creatinine 1.5 ULN or creatinine clearance > 60 mL / min
For patients with pulmonary lesions or previous lung irradiation who are known or suspected to have impaired lung function, the forced expiratory volume (FEV1) for 1 second of lung function must be above 1L
Female subjects of childbearing age must have a negative urine or serum pregnancy test within 72 hours prior to randomization. Subjects agreed to adequate contraception during the trial
The patient is voluntarily enrolled and obtained the informed consent form signed by the patient or his legal representative

Exclusion Criteria

Primary tumor of esophagus is confirmed uncontrolled or progressive by imaging or gastroscope,or any esophageal or nodal recurrence locates in the previous radiation field
The pathological diagnosis of any metastatic lesion is clearly different from the primary tumor or diagnosed as a second primary tumor
Patients participated in any investigational drug study within 4 weeks preceding the start of treatment
If there is a metastasis within 3 months after definitive treatment, or the number of metastases is more than 4
Patients with uncontrolled brain metastases, or vertebral body metastasis with spinal cord compression symptoms
Patients with uncontrolled pleural, pericardial or pelvic effusion that requires repeated drainage
Patients who have received chemotherapy, anti-tumor medication, major surgery or severe trauma within 3 months before enrollment
Pregnant or breastfeeding women
Patients with history of immunodeficiency, or severe medical diseases that are not well controlled, which may have effect on the treatment of this study
Any other malignant tumor was diagnosed within 5 years prior to or after the diagnosis of ESCC, except for malignant tumors with a low risk of metastasis and death (5-year survival rate >90%), such as well-treated basal cells or squamous cell skin cancer or cervical cancer in situ
The investigator judged that patients could not cooperate with the treatment, or have other factors that might cause him to be forced to terminate the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note